This white paper highlights how pharmaceutical and medical device companies can demonstrate the value of Independent Medical Education (IME) programs. It addresses compliance obligations, separation from commercial influence, and stakeholder communication challenges. It advises creating grant strategies aligned with patient outcomes, leveraging data-driven impact measurement, and adopting technology for transparency. By showing how IME supports healthcare provider competence and better patient outcomes, companies can justify investments while safeguarding compliance and reputation.

Join for free to read